DK1897546T3 - Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre - Google Patents

Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre

Info

Publication number
DK1897546T3
DK1897546T3 DK07008956.0T DK07008956T DK1897546T3 DK 1897546 T3 DK1897546 T3 DK 1897546T3 DK 07008956 T DK07008956 T DK 07008956T DK 1897546 T3 DK1897546 T3 DK 1897546T3
Authority
DK
Denmark
Prior art keywords
enoinsyre
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
Prior art date
Application number
DK07008956.0T
Other languages
English (en)
Inventor
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Astrazeneca Ab
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Application filed by Astrazeneca Ab, Univ Aberdeen filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1897546T3 publication Critical patent/DK1897546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07008956.0T 1999-02-06 2000-02-01 Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre DK1897546T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
EP00901744A EP1150678B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (1)

Publication Number Publication Date
DK1897546T3 true DK1897546T3 (da) 2011-01-17

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00901744T DK1150678T3 (da) 1999-02-06 2000-02-01 Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati
DK07008956.0T DK1897546T3 (da) 1999-02-06 2000-02-01 Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00901744T DK1150678T3 (da) 1999-02-06 2000-02-01 Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati

Country Status (34)

Country Link
US (4) US6894058B1 (da)
EP (2) EP1150678B1 (da)
JP (3) JP2002536332A (da)
KR (1) KR100699757B1 (da)
CN (1) CN1196488C (da)
AR (1) AR025512A1 (da)
AT (2) ATE367162T1 (da)
AU (1) AU763970B2 (da)
BR (1) BR0007996A (da)
CA (1) CA2368186C (da)
CY (2) CY1106879T1 (da)
CZ (2) CZ302881B6 (da)
DE (2) DE60045168D1 (da)
DK (2) DK1150678T3 (da)
EE (2) EE05621B1 (da)
ES (2) ES2286995T3 (da)
GB (1) GB0001662D0 (da)
HK (2) HK1041223A1 (da)
HU (1) HU227642B1 (da)
IL (3) IL144730A0 (da)
IS (2) IS2793B (da)
MX (1) MXPA01007821A (da)
MY (1) MY138289A (da)
NO (1) NO330400B1 (da)
NZ (3) NZ525419A (da)
PL (1) PL198098B1 (da)
PT (2) PT1897546E (da)
RU (1) RU2239456C2 (da)
SI (2) SI1150678T1 (da)
SK (2) SK287792B6 (da)
TR (1) TR200102229T2 (da)
TW (1) TWI230067B (da)
WO (1) WO2000045818A1 (da)
ZA (1) ZA200105885B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
PL361097A1 (en) * 2000-10-12 2004-09-20 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
WO2002032411A2 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
MXPA03004871A (es) 2000-11-30 2003-08-19 Pfizer Prod Inc Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa.
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
TW200305415A (en) * 2002-03-22 2003-11-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
WO2004096276A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited 糖取り込み能増強剤
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1643999B8 (en) * 2003-06-20 2012-03-14 NephroGenex, Inc. Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2003272084A1 (en) * 2003-10-07 2005-04-21 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-Beta,Delta,6-TRIHYDROXY-2-METHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (BetaR,Delta R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
ES2639019T3 (es) 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. Nuevo cocristal de colina de epalrestat
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
IN2014CN04119A (da) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
ATE181830T1 (de) 1992-04-13 1999-07-15 Zeneca Ltd Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
EP0754042A4 (en) * 1994-03-29 2004-06-23 Merck & Co Inc TREATING ATHEROSCLEROSIS WITH IMIDAZOLES BLOCKING THE ANGIOTENSIN II RECEPTOR
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CZ297941B6 (cs) 1996-04-05 2007-05-02 Takeda Pharmaceutical Company Limited Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
CZ20012806A3 (cs) 2002-02-13
TR200102229T2 (tr) 2001-12-21
EE200100405A (et) 2002-10-15
IS8978A (is) 2011-08-23
ES2286995T3 (es) 2007-12-16
NZ513061A (en) 2003-06-30
JP2012051898A (ja) 2012-03-15
AR025512A1 (es) 2002-12-04
US6894058B1 (en) 2005-05-17
EP1150678A1 (en) 2001-11-07
ZA200105885B (en) 2002-10-17
CY1110992T1 (el) 2015-06-11
NO330400B1 (no) 2011-04-04
ES2352803T3 (es) 2011-02-23
WO2000045818A1 (en) 2000-08-10
PL198098B1 (pl) 2008-05-30
IS6016A (is) 2001-07-20
HUP0105138A3 (en) 2002-11-28
RU2239456C2 (ru) 2004-11-10
DK1150678T3 (da) 2007-10-08
CN1338937A (zh) 2002-03-06
NZ536433A (en) 2006-08-31
EE201200015A (et) 2012-10-15
JP2014065718A (ja) 2014-04-17
HUP0105138A2 (hu) 2002-04-29
SK286854B6 (sk) 2009-06-05
KR20010089635A (ko) 2001-10-06
BR0007996A (pt) 2001-10-30
NZ525419A (en) 2004-12-24
GB0001662D0 (en) 2000-03-15
IS2820B (is) 2012-12-15
CZ302881B6 (cs) 2012-01-04
IL144730A (en) 2010-12-30
MXPA01007821A (es) 2004-08-19
EP1150678B1 (en) 2007-07-18
EP1897546B1 (en) 2010-10-27
EE05556B1 (et) 2012-08-15
CA2368186A1 (en) 2000-08-10
ATE485823T1 (de) 2010-11-15
DE60035575D1 (de) 2007-08-30
SK11102001A3 (sk) 2002-05-09
US20050209128A1 (en) 2005-09-22
SK287792B6 (sk) 2011-10-04
IL144730A0 (en) 2002-06-30
CY1106879T1 (el) 2012-05-23
HK1041223A1 (en) 2002-07-05
TWI230067B (en) 2005-04-01
AU2304700A (en) 2000-08-25
SI1897546T1 (sl) 2011-02-28
AU763970B2 (en) 2003-08-07
US20120041010A1 (en) 2012-02-16
MY138289A (en) 2009-05-29
CN1196488C (zh) 2005-04-13
HK1118209A1 (en) 2009-02-06
CA2368186C (en) 2008-06-03
DE60045168D1 (de) 2010-12-09
HU227642B1 (en) 2011-10-28
IS2793B (is) 2012-08-15
SI1150678T1 (sl) 2008-02-29
EP1897546A1 (en) 2008-03-12
PL350312A1 (en) 2002-12-02
KR100699757B1 (ko) 2007-03-27
JP2002536332A (ja) 2002-10-29
NO20013812L (no) 2001-10-02
PT1150678E (pt) 2007-09-14
CZ302893B6 (cs) 2012-01-11
IL208330A0 (en) 2010-12-30
DE60035575T2 (de) 2008-04-03
PT1897546E (pt) 2010-12-15
ATE367162T1 (de) 2007-08-15
EE05621B1 (et) 2013-02-15

Similar Documents

Publication Publication Date Title
DK1897546T3 (da) Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
EE05586B1 (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
ZA200205331B (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid.
DK1682536T3 (da) Fremgangsmåde til fremstilling af calciumsaltet af rosuvastatin (e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensyre og krystallinske mellemprodukter deraf
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
CA2429263A1 (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS2337B (is) Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4